• 1
    Levi M, ten Cate H, van der Poll T et al. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270:9759.
  • 2
    Hendin RI. Disorders of coagulation and thrombosis. In: Isselba-cherKJ, BraunwaldE, WilsonJD et al. eds. Harrison's principles of internal medicine. New York : McGraw-Hill, Inc., 1994: 18078.
  • 3
    Bevilacqua M, Prober JS, Majeau GR et al. Recombinant tumor necrosis factor induces procoagulant activity in human vascular endothelium: characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA 1986; 83:45337.
  • 4
    Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163:7405.
  • 5
    Bauer KA, ten Cate H, Barzegar S et al. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 1989; 74:16572.
  • 6
    Bevilacqua M, Pober JS, Majeau GR et al. Interleukin 1(IL-1) induces biosynthesis and cell expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160:61823.
  • 7
    Warr TA, Rao LVM, Rapaport SA. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75:14819.
  • 8
    Kawamura M, Terashita Z, Imura Y et al. Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation. Thromb Res 1993; 70:28193.
  • 9
    Imura Y, Terashita Z, Nishikawa K. Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988. Life Sci 1986; 39:1117.
  • 10
    Imanishi N, Komuro Y, Morooka S. Effect of a selective PAF antagonist SM-10661 ((+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one HC1) on experimental disseminated intra-vascular coagulation (DIC). Lipids 1991; 26:13915.
  • 11
    Ishizaka T, Ishizaka K. Biology of immunoglobulin E: molecular basis of reagenic hypersensitivity. Prop Allergy 1975; 19:60121.
  • 12
    Braquet P, Etienne A, Touvay C et al. Involvement of platelet-activating factor in respiratory anaphylaxis. demonstrated by PAF-acether inhibitor BN 52021. Lancet 1985; 1:1501.
  • 13
    Vilain B, Lagentle V, Touvay C et al. Pharmacological control of the in vivo passive anaphylalaxis shock by the PAF-acether antagonist compound BN 52021. Pharmacol Res Commun (suppl.) 1986; 18:11926.
  • 14
    Arimura A, Nagata M, Watanabe A et al. Production of active and passive anaphylactic shock in the WBB6F1 mouse, a mast cell-deficient strain. Experimentia 1990; 46:73942.
  • 15
    Herbert JM, Lespy L, Maffrand JP. Protective effect of SR 27417, a novel PAF antagonist, on lethal anaphylactic and endotoxin-induced shock in mice. Eur J Pharmacol 1991; 205:2716.
  • 16
    Braquet P, Touqui L, Shen TY et al. Perspectives in platelet-activing factor research. Pharmacol Rev 1987; 39:97145.
  • 17
    Ha TY, Reed ND. Immune response potential of mast cell-deficient W/Wv mice. Int Archs Allergy appl Immunol 1986; 80:6394.
  • 18
    Ha TY, Reed ND. Systemic anaphylaxis in mast cell-deficient mice of W/Wv and S1/S1d genotypes. Expl Cell Biol 1987; 55:6368.
  • 19
    Brecher G, Schneiderman M, Eugene P et al. The reproduction and constancy of the platelet count. Amer J Clin Pathol 1953; 23:1526.
  • 20
    Terashita Z, Imura Y, Nishikawa K. Inhibition by CV-3988 of the binding of [3H]-platelet activing factor (PAF) to the platelet. Biochem Pharmacol 1985; 34:14915.
  • 21
    Bussolino F, Breviario F, Tetta C et al. Interleukin I stimulates platelet-activating factor production in human endothelial cells. J Clin Invest 1986; 77:202733.
  • 22
    Camussi G, Bussolino F, Sulvidio G et al. Tumor necrosis factor/cachectin stimulates peritoneal macrophage. polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med 1987; 166:1390404.
  • 23
    Valone FH, Epstein LB. Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1, tumor necrosis factor, or IFN. J Immunol 1988; 141:394550.
  • 24
    Camussi G, Tetta C, Bussolino F et al. Synthesis and release of platelet-activating factor is inhibited by plasma α1-proteinase inhibitor or α1-antichymotrypsin and is stimulated by proteinase. J Exp Med 1988; 168:1293306.